article
Pharmaceutical C-suite update
With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.
List view / Grid view
Vaccine Technology
news
Bavarian Nordic to supply EU Member States with monkeypox vaccine
Bavarian Nordic has announced it will supply 110,000 doses of its MVA-BN smallpox/monkeypox vaccine to the European Health Emergency Preparedness and Response Authority (HERA) over the coming months.
news
Individualised mRNA vaccine shows promise in pancreatic cancer patients
Phase I study shows that mRNA-based individualised neoantigen specific immunotherapy (iNeST) vaccines can be used to stimulate T cells to recognise neoantigens in pancreatic cancer patients.
news
GSK to acquire Affinivax for MAPS vaccine platform
GSK will pay up to $3.3 billion to acquire Affinivax, gaining access to its Multiple Antigen Presenting System (MAPS) technology and pneumococcal vaccine candidates.
podcasts
EPR Podcast Episode 11 – Developing vaccine technologies – Giulia Giordano and Mark Doherty, GSK
Why is vaccine manufacturing becoming more biological? How could Generalized Modules for Membrane Antigens (GMMA) enhance vaccinology? What developments have there been in adjuvant systems? Discover all this and more in this podcast with GSK experts.
news
WEVEE vaccine shows promise against trio of rare but deadly viruses
Phase I trial data suggests that a vaccine targeting three mosquito-borne encephalitis viruses is safe and can elicit an immune response.
article
The future of vaccine research and learning the lessons of COVID-19
Dr Owen Seddon, Consultant in Infectious Diseases and Medical Microbiology at University Hospital of Wales, explains how successes in the development of the coronavirus vaccine must be used in the fight against other vaccine preventable disease.
news
Left-handed gold nanoparticles improve vaccine efficacy by more than 25 percent, finds study
The results of a recent international study suggest that left-handed gold nanoparticles can increase vaccine effectiveness by 25 percent, providing useful adjuvant capabilities.
news
Designed for success – new SNA vaccine proves highly effective in mice
A team of scientists has developed a spherical nucleic acid (SNA) vaccine, which has demonstrated high efficacy as a COVID-19 therapy, as well as an anti-cancer treatment in rodents.
news
Moderna launches two new mRNA vaccine programmes
The new mRNA vaccine programmes are aimed at the major causative agents of respiratory tract infections, respiratory syncytial virus (RSV), influenza and coronaviruses.
news
Intravacc publishes GMP vaccine candidate manufacturing process
A new paper details the GMP manufacturing and formulation process for a semi-synthetic Shigella glycoconjugate vaccine candidate from Institut Pasteur.
news
mRNA vaccine candidates for HIV enter Phase I trial
Will mRNA vaccines one day protect against HIV? Three investigational mRNA vaccines, all designed to combat HIV, have entered Phase I testing.
news
USP calls for industry input in developing mRNA quality guidelines
USP is developing mRNA quality guidelines to support the development of innovative medicines and vaccines.
news
Could COVID-19 vaccines be swallowed?
New pre-clinical research demonstrates the potential of gastric autoinjectors to deliver mRNA in sufficient quantities for vaccination.
news
First patients dosed in HIV vaccine immunogens trial
Moderna and IAVI take steps towards HIV vaccination, with initiation of a trial dosing patients with HIV immunogens delivered by mRNA.
